HCPCS code J0714 – Ceftazidime-avibactam injection billing

Key takeaways

HCPCS code J0714 covers ceftazidime-avibactam (Avycaz) injection, and one billing unit equals 0.5 g ceftazidime plus 0.125 g avibactam. The standard adult dose is one 2 g/0.5 g vial, which bills as 4 units per infusion.

Medicare Part B pays J0714 at ASP+6% in the physician office, while hospital outpatient departments are paid under OPPS. Inpatient use is bundled into the Part A DRG.

Medicaid and most commercial payers require the 11-digit NDC alongside J0714, reported with the UN qualifier and a quantity of 1 per vial.

Report modifier JW on a separate line for discarded drug, or modifier JZ when no drug was discarded.

Always bill J0714 with an infusion administration code, such as CPT 96365 for the first hour.

HCPCS code J0714: Definition and code descriptor

HCPCS code J0714 is the Level II code that CMS assigns to “Injection, ceftazidime and avibactam, 0.5 g/0.125 g.” It is the specific, permanently assigned code for Avycaz and is active for 2026. Each unit covers 0.5 g of ceftazidime, so the standard 2 g adult dose bills as 4 units.

Ceftazidime-avibactam is a combination beta-lactam/beta-lactamase inhibitor antibiotic. Ceftazidime targets gram-negative bacteria, and avibactam protects it from breakdown by extended-spectrum beta-lactamases. The combination is given intravenously. There is no oral formulation, and J0714 does not apply to any non-injectable route.

Clinical indications for J0714 ceftazidime-avibactam

J0714 covers Avycaz given for its FDA-approved indications. Off-label use is a compliance risk and draws heightened payer scrutiny, so confirm the diagnosis supports an approved indication before billing.

The FDA-approved indications for ceftazidime-avibactam (Avycaz) are:

• Complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible gram-negative organisms
• Complicated intra-abdominal infections (cIAI), used in combination with metronidazole
• Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible gram-negative organisms

J0714 does not apply to oral ceftazidime-avibactam (none is FDA-approved), non-injectable routes, or ceftazidime given alone without avibactam. Payers expect a diagnosis code that maps directly to one of these indications on every claim.

Billing units: How to calculate J0714 units

One billing unit of J0714 equals 0.5 g ceftazidime plus 0.125 g avibactam. Each Avycaz vial contains 2 g ceftazidime and 0.5 g avibactam. Most infusion protocols dose at 2 g/0.5 g (2.5 g combined) every 8 hours, which equals 4 units per infusion.

Report the units that match the dose administered, rather than the number of vials opened. When part of a vial is discarded, report the discarded units on a separate line with modifier JW. The documentation section below lists what the record needs to support that line.

Formula: Divide the ceftazidime grams administered by 0.5 to get the unit count. A 2 g ceftazidime dose divided by 0.5 = 4 units of J0714.

The unit count is the first of five entries on a J0714 claim line, and the diagram below shows the other four.

2026 Medicare fee schedule and reimbursement rates for J0714

Medicare Part B pays HCPCS code J0714 at ASP+6% (average sales price plus 6%) in the physician office (POS 11). Hospital outpatient departments (POS 19/22) are paid under OPPS (Addendum B). The ASP-based payment limit changes each quarter when CMS releases updated pricing files.

Because ASP rates shift quarterly, a hard-coded dollar figure here would be outdated by the time claims are filed. Check the current payment limit in the CMS ASP Drug Pricing Files. Filter by HCPCS code J0714 and select the applicable quarter.

Avycaz is not on the self-administered drug exclusion lists published by Medicare Administrative Contractors (for example Palmetto GBA’s Article A53066). It therefore qualifies for Part B coverage when a provider administers it in an eligible setting.

Place of service and coverage settings for HCPCS code J0714

J0714 is separately billable only when the patient is in an outpatient or non-facility setting. For an inpatient, the drug cost is bundled into the Medicare Part A DRG payment. Billing J0714 separately for an inpatient encounter will result in denial.

NDC reporting requirements for J0714

Medicaid and most commercial payers require the 11-digit National Drug Code (NDC) reported alongside HCPCS code J0714 on the claim. A missing or mismatched NDC is one of the most common denial triggers for this code.

Report the NDC in the 5-4-2 format (labeler-product-package), for example 00456-2700-10, the Avycaz carton of 10 vials (4 billing units per vial). The NDC unit qualifier for J0714 is UN (unit), with a quantity of 1 per vial. Verify the current Avycaz NDC against the vial label before billing. Packaging changes can create a new NDC that differs from the one the system has on file.

• NDC placement on the claim: Report it in the shaded area of box 24 on the CMS-1500 form (loop 2410 of the 837P electronic claim).
• NDC quantity: Report the quantity in NDC units (UN), one per vial. Avycaz is a powder, not a measured liquid.
• NDC unit qualifier: Use UN for Avycaz powder vials.
• Payer verification: Some Medicare Administrative Contractors (MACs) require the NDC on Part B claims too, so check your MAC’s policy.

Cross-reference the NDC on the vial against the AAPC HCPCS code reference and the manufacturer’s current labeling before each billing cycle. That check confirms the code-to-NDC pairing is still valid.

Administration codes required alongside J0714

J0714 is the drug code only. It does not cover the provider’s work in administering the infusion. Providers bill a companion infusion administration code on the same claim, most often CPT 96365 for the first hour.

Modifiers JW and JZ (drug wastage): When part of a vial is discarded, report the wasted units on a separate J0714 line with modifier JW. Report modifier JZ on the J0714 line when no drug was discarded. Medicare has required one of the two on single-dose container drug claims since July 1, 2023. Document the lot number, the amount discarded, and the reason for waste in the medical record.

Prior authorization requirements for J0714

Medicare Part B generally does not require prior authorization (PA) for HCPCS code J0714 in outpatient settings. Most Medicaid managed care plans and commercial payers do. Billing without an approved PA when one is required is a top denial reason.

The typical prior authorization workflow for J0714 includes:

1. Confirm the diagnosis with culture and sensitivity results that support a J0714-covered indication
2. Obtain an infectious disease or specialist attestation that alternative antibiotics were considered or failed
3. Submit PA documentation to the payer before the first infusion, as many plans require 48–72 hours’ notice
4. Record the PA approval number in the patient chart and include it on the claim when required
5. Verify PA duration, since some plans approve J0714 for a fixed treatment course and need re-authorization if the course runs longer

PA requirements vary by payer, plan, and state. Never assume Medicare’s no-PA default applies to commercial or Medicaid claims. Check each payer’s policy for J0714 specifically, as some plans have added PA requirements for high-cost antibiotics in recent years.

J0714 vs J3490: When to use each code

J0714 is the permanently assigned, specific HCPCS code for ceftazidime-avibactam. J3490 is the unclassified fallback for drugs that have no specific J code. Using J3490 when J0714 is available is a billing error that routinely triggers denial or audit.

Before defaulting to J3490, verify that the payer’s system recognizes J0714. Medicare and most major payers have loaded this code. If a payer rejects J0714 with an “invalid code” error, call the payer to confirm. That rejection usually points to a lag in the payer’s system rather than a missing code.

Common J0714 claim denial reasons and corrective actions

Most J0714 denials fall into six categories, and each one has a clear corrective path. For the reason codes payers attach to these rejections, see our guide to denial codes.

Systematic denial management workflows and pre-submission audits clear most of these issues before the claim reaches the payer. Pabau, the practice management platform we build, includes claims management software that flags missing companion codes and NDCs when the claim is created.

Documentation requirements for J0714 claims

Every J0714 claim needs medical record documentation that survives a payer audit and supports any PA appeal. Complete records are also a core element of medical billing compliance for high-cost injectable drugs.

• Diagnosis codes: ICD-10-CM codes that directly support a J0714-approved indication (cUTI, cIAI, or HABP/VABP)
• Culture and sensitivity results: Microbiology report demonstrating susceptibility to ceftazidime-avibactam
• Prescriber order: Signed order specifying Avycaz dose, frequency, and route
• Infusion nursing notes: Start and stop time, drug lot number, dose administered, and the infusion site
• NDC from the vial label: Recorded at the time of administration, never copied from a formulary reference
• Wastage documentation: If modifier JW is reported, note the amount discarded and the reason
• PA approval number: When prior authorization was required and granted, include the approval reference on the claim

Under the HCPCS Level II coding framework, three items resolve most J0714 documentation problems before they reach the payer. They are an accurate NDC, the correct unit count, and a diagnosis code that maps to an FDA-approved indication.

How claims management software prevents J0714 denials

A J0714 claim draws on three separate records. The nursing note holds the dose, the vial label holds the NDC, and the payer portal holds the PA number. Each hand-off between them is a point where a unit count or a modifier can drop off the claim.

Pabau keeps the drug code, the administration code, the NDC and the PA number on a single claim screen. Your billing team sees the whole J0714 line, units and JW or JZ modifier included, before the claim leaves the practice.

The result is fewer first-pass denials on a high-cost drug, where one rejected claim can hold up payment for weeks.

Track J0714 claims from order to payment

Pabau’s claims management software keeps drug codes, NDCs, administration codes and PA numbers in one claim workflow. Your team can check every J0714 line before submission.

Book a demo

Conclusion

The quickest win on J0714 is to treat the standard dose as a fixed pattern. One 2 g/0.5 g vial is 4 units, one NDC unit under the UN qualifier, a JZ modifier, and an administration code such as 96365. Any claim that departs from that pattern deserves a second look before it goes out.

Check the place of service before the units, because it decides whether the units are paid at all. The same infusion earns ASP+6% in the physician office and the OPPS rate in a hospital outpatient department. As an inpatient line, it is not paid separately.

For the wider workflow these steps belong to, see our overview of medical billing. Book a demo to see how Pabau puts the dose, NDC and modifiers for J0714 on one claim screen before it reaches the payer.

Continue your research

Need to understand how clearinghouse submissions work for drug codes? Medical claims clearinghouse overview explains how drug J codes move from the practice to the payer electronically.

Wondering how to handle a J0714 claim that came back with a denial code? Denial management in healthcare covers the appeal process and denial tracking workflows.

Looking for a billing compliance checklist to use alongside this guide? Medical billing compliance outlines the documentation and audit-readiness standards that apply to Part B drug claims.

Frequently asked questions